1b) Now you can earn ANOTHER 0.5h credit with Joseph Mikhael MD @jmikhaelmd of @TGEN & #CMO of @IMFmyeloma, the 🥇& largest org dedicated to #multiplemyeloma. @jmikhaelmd is Professor in the Applied Cancer Research & Drug Discovery Division at @TGen. pic.twitter.com/JbAYO8DHPR
— @onc_ce (@onc_ce) February 9, 2023
3) Each year, myeloma sessions at @ASH_hematologySummit have different patterns of interest and importance. This year, #bispecific antibodies became the area of great excitement, with results from many trials reported. @Bethfaiman has already introduced us to some of those data.
— @onc_ce (@onc_ce) February 9, 2023
5) The two other key targets are #GPRC5D and #FcRH5. These are both prolifically expressed on #MM cells and are genuinely distinct from #BCMA. We now have therapies in both #CART and #bispecifics being developed for these targets.
— @onc_ce (@onc_ce) February 9, 2023
6b) #Talquetamab had remarkable efficacy of over 70% in heavily pretreated #MM patients with nearly 60% of patients achieving a #VGPR or better. Even in patients with prior #T_cell redirection therapies, the response rate was approx 62% pic.twitter.com/soheU1MfbR
— @onc_ce (@onc_ce) February 9, 2023
6d) #CRS remains common (60-65%) although the infection signal may be somewhat lower than in BCMA directed therapies.
— @onc_ce (@onc_ce) February 9, 2023
🗓️#Talquetamab is moving through the approval process and may make its way to clinic as soon as late 2023… pic.twitter.com/UHzrefCpla
7b) Although we need more data, there were clear racial and ethnic differences in both response to #CART and toxicities from CART. Key trends included response and duration of response appears to be lower in Hispanic patients when compared to non-Hispanic patients pic.twitter.com/do0wUqLYNU
— @onc_ce (@onc_ce) February 9, 2023
7d) We have massive #disparities to overcome in #MM – these kinds of studies are needed to better understand the nature of these disparities and how these novel therapies are optimally used. pic.twitter.com/HKqkReyGSC
— @onc_ce (@onc_ce) February 9, 2023
8b) #Modakafusp introduces a new #MOA in #MM and may be an alternative to #CART and #bispecifics. pic.twitter.com/0mY0EZhnRE
— @onc_ce (@onc_ce) February 9, 2023
8c) ORR impressive at 43% in heavily pretreated patients, even those with prior #BCMA therapies including #CART pic.twitter.com/p1pzsrRRPB
— @onc_ce (@onc_ce) February 9, 2023
9a) With nearly 1000 abstracts in #MM, there was so much to learn at ASH22. One important theme was exploring ways to stop therapy in patients – as now most MM pts remain on indefinite therapy during multiple lines of therapy.
— @onc_ce (@onc_ce) February 9, 2023
10a) An important study evaluating the length of maintenance therapy with #lenalidomide was presented as Abstract 570 by Charlotte Pawlyn @_DrCP 🇬🇧. pic.twitter.com/DX3fk5zslJ
— @onc_ce (@onc_ce) February 9, 2023
11a) Lastly, it was encouraging to see how the novel triplet regimen of #isatuximab, #carfilzomib and #dexamethasone continues to demonstrate benefit in multiple subgroups. pic.twitter.com/K7lBJkwhxW
— @onc_ce (@onc_ce) February 9, 2023
12) So what have you learned?
— @onc_ce (@onc_ce) February 9, 2023
1⃣Talquetamab is novel bispecific antibody that targets the following antigen on the cell surface:
14) It's c!
— @onc_ce (@onc_ce) February 9, 2023
And 3⃣In the updated analysis of the #IKEMA trial, the triplet combination of #Isatuximab, #Carfilzomib and #Dex yields a PFS of approximately
15b) (cont)
— @onc_ce (@onc_ce) February 9, 2023
*⃣ ongoing therapy remains the #SOC, but we are working on ways to stop so our patients can be treatment free!
*⃣ newer approaches are on the way including small and large molecules that can be easily delivered
16) I am @jmikhaelmd and that wraps up my contribution to the #RRMM highlights from #ASH2022! Go to https://t.co/SaHQ4yPLPW to claim your 🆓CE/#CME 🇺🇸🇨🇦🇪🇺🇬🇧. And please FOLLOW US here on @onc_ce for the latest professional education on advances in #oncology! pic.twitter.com/PRTHxbkpjQ
— @onc_ce (@onc_ce) February 9, 2023